摘要
目的探究与分析肝素联合尿激酶治疗下肢静脉血栓形成的影响。方法选取北京市石景山医院胸血管外科收治的90例下肢静脉血栓患者,采取随机数字表法分为对照组45例与试验组45例,对照组给予单纯低分子肝素治疗,试验组在对照组基础上加用小剂量尿激酶静滴治疗,7天为1个疗程,共2个疗程。对比2组治疗前后下肢静脉通畅率变化、凝血功能指标、不良反应及复发率。结果试验组治疗后明显优于对照组治疗后股静脉、腘静脉及胫后静脉通畅率(P<0.05);试验组治疗后较对照组治疗后PT、APTT、TT时间明显减少(P<0.05);试验组不良反应发生率明显低于对照组(P<0.05);试验组随访1年的复发率明显低于对照组(P<0.05)。结论采用低分子肝素联合尿激酶治疗下肢静脉血栓形成的远期临床疗效显著且预后较好。
Objective To explore and analyze effect of heparin combined with urokinase therapy on lower limb venous thrombosis. Methods 90 cases with lower extremity venous thrombosis were chosed and divided into control group of 45 cases and experimental group of 45 cases according with random number table method. Control group was given pure low molecular heparin treatment,experimental group was treated with small dose of urokinase static drop on the basis of control group,7 days for a course,a total of 2 course of treatment. Compared two groups before and after treatment of lower limb venous patency rate changes,blood coagulation function index,adverse reactions and the recurrence rate. Results Compared with control group post-treatment. patency rate of posterior divisions,popliteal vein and posterior tibial vein of experimental group were significantly better( P〈0. 05).Experimental group post-treatment compared with control group post-treatment,PT,APTT,TT time had significant difference( P〈0. 05). Patients incidence of adverse reactions were significantly lower than control group( P〈0. 05). Patients were followed up for 1 year recurrence rate was significantly lower than control group( P〈0. 05). Conclusion Effect of low molecular heparin combined with urokinase in the treatment of venous thrombosis of lower limbs significant and its prognosis is well.
出处
《中国生化药物杂志》
CAS
2015年第11期124-126,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
低分子肝素
尿激酶
下肢静脉血栓
疗效
low molecular heparin
urokinase
lower limb venous thrombosis
curative effect